Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | NPBWR1 | P48145 | 2/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16690383 | 0.87 | NOTUM (0.38) | MAPT | |
| SCHEMBL16690347 | 0.85 | PKM (0.41) | FFAR1PPARGNPBWR1MAPT | |
| SCHEMBL16690381 | 0.83 | FFAR1 (0.43) | FFAR1P2RX3FAAH | |
| SCHEMBL16690384 | 0.83 | SCN8A (0.43) | FFAR1MAPTBRD4 | |
| SCHEMBL16690405 | 0.82 | PKM (0.43) | MAPTBRD4 | |
| SCHEMBL18037158 | 0.79 | TP53 (0.36) | FAAHMAPTBRD4 | |
| SCHEMBL16690379 | 0.78 | MAPT (0.36) | MAPT | |
| SCHEMBL16690344 | 0.78 | PKM (0.39) | MAPT | |
| SCHEMBL16442879 | 0.77 | SLC22A12 (0.36) | FFAR1PPARGMAPTBRD4 | |
| SCHEMBL16683839 | 0.77 | LMNA (0.41) | PPARGSLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160249617-A1 | TETRAZOLINONE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-09-01 | — | — | US | disclosed |
| US-20160249617-A1 | TETRAZOLINONE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-09-01 | — | — | US | disclosed |
| WO-2015064727-A1 | TETRAZOLINONE COMPOUND AND APPLICATION FOR SAME | 住友化学株式会社 | 2015-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160249617-A1 | TETRAZOLINONE COMPOUND AND USE THEREOF | TCOF1, TAOK2, CYC1 | FFAR1 919/4885P2RX3 3097/4885FAAH 4116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.